Repligen Co. (NASDAQ:RGEN - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Friday . The stock traded as low as $106.78 and last traded at $108.67, with a volume of 296171 shares. The stock had previously closed at $121.70.
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $180.00 price target on shares of Repligen in a research report on Friday, February 21st. Evercore ISI initiated coverage on Repligen in a report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price target on the stock. Canaccord Genuity Group initiated coverage on Repligen in a research note on Tuesday, December 17th. They set a "hold" rating and a $165.00 price objective for the company. Canaccord Genuity Group lifted their target price on Repligen from $165.00 to $170.00 and gave the company a "hold" rating in a research note on Friday, February 21st. Finally, JPMorgan Chase & Co. increased their price target on shares of Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. Seven research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, Repligen has a consensus rating of "Moderate Buy" and an average target price of $178.64.
View Our Latest Analysis on RGEN
Repligen Stock Up 13.7 %
The stock has a market capitalization of $6.95 billion, a PE ratio of -242.84, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The business's fifty day moving average price is $146.48 and its two-hundred day moving average price is $146.91.
Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating analysts' consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. On average, equities research analysts forecast that Repligen Co. will post 1.72 EPS for the current fiscal year.
Insider Buying and Selling at Repligen
In other Repligen news, Director Margaret Pax bought 250 shares of Repligen stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average price of $150.69 per share, with a total value of $37,672.50. Following the completion of the acquisition, the director now directly owns 1,043 shares in the company, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.20% of the company's stock.
Hedge Funds Weigh In On Repligen
A number of institutional investors have recently modified their holdings of RGEN. Signaturefd LLC raised its position in Repligen by 172.2% during the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 124 shares in the last quarter. Sava Infond d.o.o. purchased a new position in shares of Repligen during the 4th quarter valued at approximately $29,000. Raiffeisen Bank International AG purchased a new stake in Repligen during the fourth quarter worth $29,000. Resources Management Corp CT ADV acquired a new stake in Repligen during the third quarter valued at $37,000. Finally, Quarry LP grew its position in Repligen by 796.7% during the third quarter. Quarry LP now owns 269 shares of the biotechnology company's stock valued at $40,000 after buying an additional 239 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.
Repligen Company Profile
(
Get Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Read More
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
